Protara Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; this is an annual filing, not a standalone fourth-quarter report. The company filed on March 13, 2024.
Business context
Protara is a clinical-stage biopharmaceutical company developing therapies for cancer and rare diseases. Its programs are TARA-002 for non-muscle-invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), and intravenous (IV) Choline Chloride for patients receiving parenteral nutrition. None is approved, and the company has generated no revenue.
Financial performance and position
| Metric | FY2023 / Dec. 31, 2023 | FY2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $25.0 million | $16.8 million |
| General and administrative expense | $18.6 million | $20.7 million |
| Total operating expenses | $43.6 million | $67.1 million |
| Operating loss | $43.6 million | $67.1 million |
| Interest and investment income | $3.2 million | $1.1 million |
| Net loss | $40.4 million | $66.0 million |
| Net loss per share, basic and diluted | $3.57 | $5.86 |
| Cash, cash equivalents and marketable debt securities | $65.6 million | $102.3 million |
| Working capital | $62.6 million | Not stated here |
| Total stockholders’ equity | $68.3 million | $102.1 million |
Cash flow: Operating activities used $37.6 million, compared with $26.5 million in 2022. Investing activities provided $53.1 million, primarily reflecting maturities and redemptions of marketable debt securities; financing activities used $0.1 million. The company reported an accumulated deficit of $200.4 million. Revenue-based margins are not meaningful because the company has no revenue.
Debt and liquidity: The filing reports no borrowings in the balance sheet presented. Operating lease liabilities totaled approximately $5.5 million, including $1.0 million current. Management believes resources available at the financial-statement issuance date are sufficient for at least 12 months, but says additional capital will be needed to fully execute its plans. A $300 million shelf registration became effective in November 2023; no securities had been sold under it by the filing, and “baby shelf” limits may constrain use while public float is below $75 million.
Changes versus FY2022
- Net loss narrowed by $25.5 million, chiefly because FY2022 included a $29.5 million non-cash goodwill impairment charge; there was no impairment charge in 2023.
- R&D expense rose $8.2 million, primarily due to increased TARA-002 clinical and nonclinical activity.
- G&A expense fell $2.1 million, mainly from lower personnel-related costs and directors’ and officers’ insurance premiums.
- Interest and investment income increased $2.1 million, reflecting higher returns on cash and investments.
- Cash used in operations increased $11.1 million. Cash, cash equivalents and marketable securities declined $36.7 million year over year.
Programs, outlook and commentary
- TARA-002 in NMIBC: In the small Phase 1 dose-escalation group (nine patients), preliminary results included complete responses in three CIS patients at 20KE and high-grade recurrence-free survival at week 12 in five of six patients with papillary tumors. No dose-limiting toxicities were observed in the initial cohorts, and 40KE was selected for subsequent trials. These are preliminary, early-stage results, not evidence of approval or established efficacy.
- ADVANCED-1EXP was evaluating 40KE in up to 12 CIS patients; preliminary data were expected in the first half of 2024. Phase 2 ADVANCED-2 began in September 2023, targeting at least 102 patients with high-grade CIS; a pre-planned analysis of about 10 six-month-evaluable patients was expected in the second half of 2024.
- TARA-002 in LMs: STARBORN-1, a Phase 2 trial in approximately 30 pediatric patients with macrocystic or mixed-cystic LMs, began in October 2023. Historical OK-432 data support the program but are not clinical results for TARA-002. TARA-002 has FDA Rare Pediatric Disease designation and EMA orphan designation.
- IV Choline Chloride: The company completed a prospective prevalence study and shared results with the FDA. It continued discussions with the agency on the development path and clinical evidence potentially needed for an NDA. The product has FDA orphan designation for preventing choline deficiency in PN patients and fast-track designation for IFALD.
- Management expects significant expenses and losses for the foreseeable future, no near-term revenue, and a need for additional financing. It may curtail planned development if capital is unavailable on acceptable terms. No financial revenue or earnings guidance was provided.
Risks, contingencies and unusual items
- Success depends on clinical trial results, regulatory approvals, adequate financing, and the ability to manufacture through third-party contractors. The company has never completed a clinical trial as a company or submitted a BLA or NDA.
- Clinical findings disclosed to date are preliminary and based on small cohorts; later data, audit, or verification could materially change them. TARA-002 also faces safety, enrollment, competition, and commercialization risks.
- The company relies on contract research and manufacturing organizations and has no long-term commercial supply agreement. TARA-002’s Chugai-related exclusivity for access to materials and support runs through June 17, 2030, subject to earlier termination and other terms.
- Potential dilution is relevant: year-end common shares were 11.36 million, with 2.90 million options and 526,179 RSUs outstanding; preferred stock is also convertible, subject to ownership limits.
- Operating lease payments are approximately $1.3 million due within one year and $5.1 million thereafter. Additional license, royalty, milestone, and indemnification obligations may arise, but contingent amounts are not fixed or readily estimable.
- Management reported no legal proceedings expected to have a material adverse effect. The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to audit internal controls.
Important facts for investors to verify
- Actual cash burn, cash and investment balances, and financing needs in subsequent filings; confirm the stated minimum 12-month liquidity outlook against spending and trial plans.
- Final and updated ADVANCED-1/1EXP and ADVANCED-2 results, including patient counts, response durability, safety, and the meaning of the small preliminary cohorts.
- ADVANCED-2 enrollment and analysis timing, and STARBORN-1 enrollment, safety lead-in progress, and clinical results.
- FDA feedback and the evidence, timing, and cost required to advance IV Choline Chloride toward a registrational path.
- Potential share dilution from equity financing, options, RSUs, and convertible preferred stock, together with the practical availability of the shelf registration under baby-shelf limits.